The Market Institute is proud to lead a coalition of taxpayer and free market organizations in urging Congress to adopt long-overdue site-neutral payment reforms in Medicare. We coordinated the letter below to bring attention to the urgent need for policy change that eliminates unfair pricing disparities in the healthcare system. Read more…
In RealClearHealth, US Policy Editor Charles Sauer lays out a critical test for the House Debt and Oversight and Government Efficiency Committee (DOGE): will they deliver real reform or just scratch the surface? In the excerpt below, Sauer highlights how one straightforward, bipartisan fix — Site-Neutral payments in healthcare — Read more…
For millions of viewers, the Super Bowl is as much about the commercials as it is about the game. But this year, one ad sparked more than just conversation—it triggered bipartisan concern over patient safety and regulatory oversight. Hims/Hers, a telemedicine giant, ran a minute-long ad promoting its GLP-1 knockoff Read more…
In his latest article for RealClear Health, Market Institute President Charles Sauer highlights the importance of preserving patient choice in healthcare. As the CDC’s Advisory Committee on Immunization Practices (ACIP) prepares to vote on lowering the age for routine pneumococcal vaccinations, Sauer argues that both FDA-approved vaccines should be recommended. Read more…
The recent Congressional hearing on drug prices, patents, and the pharmaceutical industry has ignited a fervent debate. Unfortunately, much of the discourse has been overshadowed by misunderstandings and misinformation. A nuanced comprehension of the patent system and its pivotal role in drug innovation is essential for fostering informed discussions and Read more…
This week, 16 conservative think tanks and advocacy groups organized a coalition letter in opposition to the Biden Administration’s recent efforts to undermine the Medicare Advantage (MA) program. The letter argues that, in addition to being an extremely popular and more efficient form of coverage, Medicare Advantage stands as a protection against Read more…
In the realm of healthcare politics, a glaring power dynamic emerges: giant corporations, notably hospitals, wield disproportionate influence over policy decisions and spending. A new article in Inside Sources by Charles Sauer explores the contentious issue of “Site Neutral” payment reform, revealing how this policy discrepancy enables hospitals to charge Read more…
In a recent turn of events, Senator Bernie Sanders has raised eyebrows by calling for the subpoena of two drug company CEOs, sparking both curiosity and concern. Market Institute President Charles Sauer’s new article in Townhall delves into Sanders’ unconventional tactics, questioning the wisdom of his confrontational approach to the Read more…
In a letter addressed to Congress, and organized by Competitive Enterprise Institute, the undersigned organizations express their strong concerns regarding the Inflation Reduction Act (IRA), particularly its provisions related to prescription drug price controls. The coalition argues that the IRA’s prescription drug price control regime is unnecessary, as it focuses Read more…
The Market Institute President Charles Sauer has a new article in Real Clear Policy looking at the problems with price setting drug prices. There are attempts by the Biden Administration to use “March In” rights to implement price controls – even at the expense of future innovation. He writes: “In Read more…